Stockhub

Kancera AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 05:1905:19, 16 August 2022 >Paris 748 bytes +748 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer...."
Retrieved from "https://stockhub.co/research/Kancera_AB"